Earnings summaries and quarterly performance for Aveanna Healthcare Holdings.
Executive leadership at Aveanna Healthcare Holdings.
Board of directors at Aveanna Healthcare Holdings.
Research analysts who have asked questions during Aveanna Healthcare Holdings earnings calls.
Benjamin Hendrix
RBC Capital Markets
3 questions for AVAH
Also covers: ACHC, ADUS, AHCO +25 more
BR
Benjamin Rossi
JPMorgan Chase & Co.
3 questions for AVAH
Also covers: AMED, ARDT, CON +7 more
PC
Pito Chickering
Deutsche Bank
3 questions for AVAH
Also covers: ACHC, AHCO, BAX +18 more
Brian Tanquilut
Jefferies
2 questions for AVAH
Also covers: ACHC, ADUS, AHCO +29 more
GM
Grayson McAllister
Truist Securities
2 questions for AVAH
Also covers: GRDN, RDNT
MH
Meghan Holtz
Jefferies Financial Group Inc.
2 questions for AVAH
Also covers: AHCO, DGX, EHAB +4 more
Andrew Mok
Barclays
1 question for AVAH
Also covers: ACHC, ADUS, AGL +21 more
DM
David Macdonald
Truist Securities
1 question for AVAH
Also covers: ENSG, GRDN, OPCH +3 more
KR
Kieran Ryan
Deutsche Bank
1 question for AVAH
Also covers: AHCO, BTSG, DCGO +3 more
MM
Michael Murray
RBC Capital Markets
1 question for AVAH
Also covers: ADUS, AHCO, AMED +7 more
Raj Kumar
Stephens
1 question for AVAH
Also covers: ACHC, ADUS, ARDT +7 more
SF
Scott Fidel
Stephens Inc.
1 question for AVAH
Also covers: ACHC, ADUS, ALHC +17 more
Recent press releases and 8-K filings for AVAH.
Aveanna Healthcare Updates 2025 Guidance and Provides Initial 2026 Outlook
AVAH
Guidance Update
M&A
Revenue Acceleration/Inflection
- Aveanna Healthcare (AVAH) updated its 2025 guidance and provided initial 2026 guidance for revenue and Adjusted EBITDA.
- For 2025, revenue guidance was increased to $2.425 billion-$2.445 billion and Adjusted EBITDA to $318 million-$322 million. Initial 2026 guidance projects revenue between $2.54 billion-$2.56 billion and Adjusted EBITDA between $318 million-$322 million.
- The company achieved significant deleveraging in 2025, reducing leverage to approximately 4.6 times by the end of Q3 2025, with a near-term goal of less than four times.
- Aveanna generated $86.2 million in free cash flow as of Q3 2025 and expects to exceed $100 million for the full year 2025, with similar expectations for 2026.
- Strategic priorities for 2026 include continued organic growth driven by volume, further tuck-in M&A using free cash flow, and maintaining cost efficiencies.
6 days ago
Aveanna Healthcare Updates 2025 Guidance and Provides Initial 2026 Outlook
AVAH
Guidance Update
Revenue Acceleration/Inflection
- Aveanna Healthcare updated its 2025 guidance, projecting revenue between $2.425 billion and $2.445 billion and Adjusted EBITDA between $318 million and $322 million, both representing increases from previous guidance.
- For 2026, the company provided initial guidance of revenue between $2.54 billion and $2.56 billion and Adjusted EBITDA between $318 million and $322 million, noting a normalized 2025 Adjusted EBITDA baseline of $300 million.
- The company achieved significant deleveraging in 2025, reducing leverage by approximately three turns to 4.6 times by the end of Q3 2025, and generated $86.2 million in free cash flow as of Q3 2025.
- Strategic initiatives, including preferred payer agreements and cost efficiencies, have contributed to a 10.3% revenue CAGR and 25.5% Adjusted EBITDA CAGR over the last five years, with a long-term organic growth goal of 5%-7%.
6 days ago
Aveanna Healthcare Updates 2025 Guidance and Provides Initial 2026 Outlook
AVAH
Guidance Update
Debt Issuance
- Aveanna Healthcare (AVAH) updated its 2025 guidance, projecting revenue between $2.425 billion and $2.445 billion and adjusted EBITDA between $318 million and $322 million, both representing increases from previous guidance.
- The company provided initial 2026 guidance, forecasting revenue in the range of $2.54 billion to $2.56 billion and adjusted EBITDA between $318 million and $322 million.
- AVAH significantly reduced its leverage by approximately three turns through Q3 2025, reaching 4.6 times, with a near-term goal of less than four times.
- Aveanna generated $86.2 million in free cash flow as of Q3 2025, with expectations to exceed $100 million for the full year 2025 and similar levels in 2026.
- The company completed a refinancing of its term loan facility, extending maturity to 2032 and achieving approximately $14 million in annual interest savings.
6 days ago
Aveanna (AVAH) Updates 2025 and Provides 2026 Financial Guidance
AVAH
Guidance Update
Earnings
Revenue Acceleration/Inflection
- Aveanna (AVAH) updated its 2025 revenue guidance to a range of $2.425 billion to $2.445 billion and Adjusted EBITDA guidance to $318 million to $322 million.
- The company also issued 2026 guidance, projecting revenue between $2.54 billion and $2.56 billion and Adjusted EBITDA in the range of $318 million to $322 million.
- For Q3 2025, Aveanna reported revenue of $621.9 million and Adjusted EBITDA of $80.1 million, representing year-over-year increases of 22.2% and 67.5% respectively.
- As of September 27, 2025, Aveanna's liquidity totaled $478.7 million, including $145.9 million in cash and $227 million in revolver availability.
6 days ago
Aveanna Healthcare Holdings Inc. Updates 2025 and Announces 2026 Guidance
AVAH
Guidance Update
Earnings
Revenue Acceleration/Inflection
- Aveanna Healthcare Holdings Inc. updated its full year 2025 guidance (year ending January 3, 2026), projecting revenue between $2.425 billion and $2.445 billion and Adjusted EBITDA between $318 million and $322 million.
- For fiscal year 2025, net income is expected to be approximately $181 million to $220 million, with Normalized Adjusted EBITDA projected at $298 million to $302 million.
- The company also announced initial full year 2026 guidance (year ending January 2, 2027), anticipating revenue between $2.54 billion and $2.56 billion and Adjusted EBITDA between $318 million and $322 million.
- The financial and operational results provided are preliminary estimates and are subject to the completion of financial closing procedures and audit.
6 days ago
Aveanna Healthcare Holdings Updates 2025 and Provides Initial 2026 Guidance
AVAH
Guidance Update
Revenue Acceleration/Inflection
- Aveanna Healthcare Holdings Inc. (AVAH) announced updated full-year 2025 guidance and initial full-year 2026 guidance on January 14, 2026.
- For fiscal year 2025 (ending January 3, 2026), the company expects revenue of approximately $2.425 billion to $2.445 billion and Adjusted EBITDA of approximately $318 million to $322 million.
- Initial guidance for fiscal year 2026 (ending January 2, 2027) projects revenue between $2.54 billion and $2.56 billion and Adjusted EBITDA between $318 million and $322 million.
- The company noted that these financial results are preliminary estimates and are subject to finalization and audit.
6 days ago
Aveanna Updates 2025 Guidance and Provides 2026 Outlook
AVAH
Guidance Update
Revenue Acceleration/Inflection
Debt Issuance
- Aveanna (AVAH) increased its 2025 guidance, projecting revenue between $2.425 billion and $2.445 billion and Adjusted EBITDA between $318 million and $322 million.
- For 2026, the company anticipates revenue in the range of $2.54 billion to $2.56 billion and Adjusted EBITDA between $318 million and $322 million.
- Q3 2025 consolidated results showed revenue of $621.9 million, a 22.2% year-over-year increase, and Adjusted EBITDA of $80.1 million, up 67.5% year-over-year.
- As of September 27, 2025, Aveanna reported liquidity of $478.7 million and total variable rate debt of $1,490 million.
7 days ago
Aveanna Provides Business Update and 2025 Guidance
AVAH
Guidance Update
Revenue Acceleration/Inflection
M&A
- Aveanna updated its 2025 guidance as of Q3, expecting revenue greater than $2.375 billion and Adjusted EBITDA greater than $300 million, following 11 consecutive quarters of beating and raising guidance. In Q3 2025, the company's revenue grew 22.2% year-over-year to $622 million, and consolidated Adjusted EBITDA increased 67.5% to $80.1 million.
- The company is executing a preferred payer strategy, with 93 agreements across its segments. It anticipates 56%-60% of its managed care Private Duty Services volumes will be under these contracts by year-end 2025, aiming for mid-60s% in 2026 and low-to-mid 80s% in 2-3 years.
- Aveanna projects a long-term organic growth rate of approximately 5%-7%. Strategic M&A, like the recent ThriveSkill Pediatrics acquisition , is expected to contribute to double-digit revenue growth in 2026 and 2027.
- As of Q3 2025, Aveanna reported strong liquidity of $478 million and generated $86.2 million in free cash flow. The company has reduced its net debt leverage to 4.6 times on an LTM basis, with a strategic goal to achieve sub-four times leverage.
Dec 9, 2025, 5:30 PM
Aveanna Healthcare Updates Strategic Plan and Financial Outlook
AVAH
Guidance Update
Revenue Acceleration/Inflection
M&A
- Aveanna Healthcare reported strong Q3 2025 revenues of $622 million, an increase of 22.2% year-over-year, and Adjusted EBITDA of $80.1 million, up 67.5% year-over-year. The company updated its 2025 guidance to expect revenue greater than $2.375 billion and Adjusted EBITDA greater than $300 million, marking its 11th consecutive quarter of beating and raising guidance.
- The company is executing a strategic plan focused on enhancing partnerships, cost efficiencies, and modernizing its Medical Solutions business, aiming for a long-term organic growth rate of 5%-7%. Aveanna expects double-digit revenue growth for 2026 and 2027, driven by volume and strategic M&A, such as the recent ThriveSkill Pediatrics acquisition.
- Aveanna is actively managing its capital structure, reporting over $478 million in liquidity and $86.2 million in free cash flow generated through Q3 2025. The company successfully refinanced its term loan facility, extending maturities to 2032 and reducing annual capital costs by $14 million, while also upsizing its revolving credit facility.
- The preferred payer strategy is gaining traction, with 93 agreements across its segments, and the company expects to align 56%-60% of its business with preferred payers by year-end 2025, targeting mid-60s% for 2026. In Q3 2025, Aveanna achieved its goal of 10 state rate increases.
Dec 9, 2025, 5:30 PM
Aveanna Healthcare Updates 2025 Guidance and Reports Strong Q3 2025 Performance
AVAH
Guidance Update
Revenue Acceleration/Inflection
M&A
- Aveanna Healthcare (AVAH) updated its 2025 guidance, expecting revenue greater than $2.375 billion and Adjusted EBITDA greater than $300 million. The company reported Q3 revenues of $622 million, up 22.2% year-over-year, and Q3 Adjusted EBITDA of $80.1 million, up 67.5% year-over-year. This marked the 11th consecutive quarter of beating and raising guidance.
- The company's strategic focus on preferred payer agreements and government affairs has led to 30 preferred payer agreements in Private Duty Services (PDS) as of Q3 2025, exceeding its goal, and 10 state rate increases. PDS, which accounts for approximately 82% of total revenue, is experiencing heightened growth.
- Aveanna aims for a long-term organic growth rate of approximately 5%-7%, with strategic tuck-in acquisitions potentially pushing annual revenue growth above 10%. The company anticipates double-digit revenue growth for 2026 and 2027, driven by volume and M&A.
- Aveanna reported $86.2 million in free cash flow generated through Q3 and strong liquidity of $478 million. Net debt leverage at the end of Q3 was 4.6 times, down three full turns in the first three quarters of the year, with a goal to be sub-four times levered. The company also refinanced its term loan facility, extending maturities to 2032 and reducing annual capital costs by about $14 million.
Dec 9, 2025, 5:30 PM
Quarterly earnings call transcripts for Aveanna Healthcare Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more